glp-1 obesity drug news today 2025 A nice article in The Hindu today highlights the New weight-loss drugs surge in
Description
Background: The evidence on berberine stimulating the secretion of GLP-1 in intestinal L cell has been studied
The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes
Preliminary research indicates they may stop cravings even before people trying to quit feel them.
This product does not contain synthetic GLP-1 and is not a GLP-1 agonist drug
In this Review, the authors discuss the potential effects of GLP-1 receptor agonists on the incidence, disease activity and progression of various forms of arthritis, as well as practical considerations for their use in this context.
Purpose of the Review Glucagon-like peptide 1 (GLP-1) receptor agonists (RA) have transformed obesity and type 2 diabetes (T2D) management
